Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Aug 30, 2024

SELL
$22.78 - $29.08 $56,950 - $72,700
-2,500 Closed
0 $0
Q2 2019

Aug 30, 2024

BUY
$15.0 - $22.49 $37,500 - $56,224
2,500 New
2,500 $55 Million

Others Institutions Holding ZYME

About Zymeworks Inc.


  • Ticker ZYME
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,694,400
  • Market Cap $903M
  • Description
  • Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...
More about ZYME
Track This Portfolio

Track Federation Des Caisses Desjardins Du Quebec Portfolio

Follow Federation Des Caisses Desjardins Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.